Cargando…

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Programmed death‐ligand 1 (PD‐L1) expression status is inadequate for indicating nivolumab in patients with non–small cell lung cancer (NSCLC). Because the baseline advanced lung cancer inflammation index (ALI) is reportedly associated with patient outcomes, we investigated whether the pretreatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiroyama, Takayuki, Suzuki, Hidekazu, Tamiya, Motohiro, Tamiya, Akihiro, Tanaka, Ayako, Okamoto, Norio, Nakahama, Kenji, Taniguchi, Yoshihiko, Isa, Shun‐ichi, Inoue, Takako, Imamura, Fumio, Atagi, Shinji, Hirashima, Tomonori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773945/ https://www.ncbi.nlm.nih.gov/pubmed/29150906 http://dx.doi.org/10.1002/cam4.1234

Ejemplares similares

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
por: Tamiya, Motohiro, et al.
Publicado: (2018)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Tamiya, Motohiro, et al.
Publicado: (2021)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment
por: Kumagai, Toru, et al.
Publicado: (2017)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis
por: HIRASHIMA, TOMONORI, et al.
Publicado: (2014)

Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis
por: Naito, Yujiro, et al.
Publicado: (2017)

Improvement of Mycobacterium abscessus Pulmonary Disease after Nivolumab Administration in a Patient with Advanced Non-small Cell Lung Cancer
por: Ishii, Seigo, et al.
Publicado: (2018)

Radial endobronchial ultrasound with a guide sheath for diagnosis of peripheral cavitary lung lesions: a retrospective study
por: Hayama, Manabu, et al.
Publicado: (2016)

The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations
por: Suzuki, Hidekazu, et al.
Publicado: (2013)

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study
por: Matsumoto, Kinnosuke, et al.
Publicado: (2021)

Retrospective analysis of long‐term survival factors in patients with advanced non‐small cell lung cancer treated with nivolumab
por: Murakami, Yusuke, et al.
Publicado: (2022)

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
por: Nakao, Keiko, et al.
Publicado: (2019)

Afatinib-induced severe esophagitis in a lung cancer patient with an activated epidermal growth factor receptor mutation: A case report
por: Inoue, Takako, et al.
Publicado: (2017)

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
por: Kanazu, Masaki, et al.
Publicado: (2020)

Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash
por: Usui, Naoko, et al.
Publicado: (2017)

Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status
por: Adachi, Yuichi, et al.
Publicado: (2019)

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
por: Kaneda, Toshihiko, et al.
Publicado: (2018)

Tree-in-bud Pattern in ALK-positive Lung Adenocarcinoma
por: Shiroyama, Takayuki, et al.
Publicado: (2020)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma
por: Masuhiro, Kentaro, et al.
Publicado: (2019)

Usefulness of High Suction Pressure for Sufficient Tissue Collection During Endobronchial Ultrasound Guided Transbronchial Needle Aspiration
por: Shiroyama, Takayuki, et al.
Publicado: (2013)

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer
por: Hida, Toyoaki, et al.
Publicado: (2017)

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
por: Shiroyama, Takayuki, et al.
Publicado: (2016)

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
por: Nasu, Shingo, et al.
Publicado: (2018)

Transformation to small cell lung cancer after first-line afatinib treatment
por: Shiroyama, Takayuki, et al.
Publicado: (2018)

Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment
por: Samejima, Yumiko, et al.
Publicado: (2020)

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
por: Oya, Yuko, et al.
Publicado: (2017)

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2017)

Prognostic Significance of Modified Advanced Lung Cancer Inflammation Index (ALI) in Patients with Small Cell Lung Cancer_ Comparison with Original ALI
por: Kim, Eun Young, et al.
Publicado: (2016)

Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study
por: Hirashima, Tomonori, et al.
Publicado: (2014)

Pembrolizumab-induced acute thrombosis: A case report
por: Kunimasa, Kei, et al.
Publicado: (2018)

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
por: Fujita, Yuya, et al.
Publicado: (2020)

Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer
por: Masuhiro, Kentaro, et al.
Publicado: (2022)

Rapid and reliable collection of tumor tissue for successful gene panel in a patient with advanced stage lung cancer: A case report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Nivolumab-induced contact dermatitis in a patient with advanced lung cancer
por: Sato, Shintaro, et al.
Publicado: (2020)

The prognostic value of the advanced lung cancer inflammation index (ALI) for patients with neuroblastoma
por: Qi, Can, et al.
Publicado: (2022)

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
por: Kudo, Fumiaki, et al.
Publicado: (2018)

Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2021)

Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
por: Hosoya, Kazutaka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c012d60gog2m09cvlttahe3fgv